PMID-22432135 – DSIP Modulates Stress-Related Fos in Limbic Structures
Sudakov KV, Umriukhin PE, Rayevsky KS. Delta sleep-inducing peptide and Deltaran: prospects of clinical application. Stress. 2001;4(4):245-254.
Quick Reference
| Property | Value |
|---|---|
| PMID | 22432135 |
| DOI | 10.3109/10253890109115726 |
| Year | 2001 |
| Journal | Stress |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rodent models under acute stress paradigms |
| Peptide(s) Studied | DSIP |
Key Findings
- DSIP administration reduced stress-induced c-Fos expression in key limbic brain structures including the amygdala, hippocampus, and hypothalamus
- c-Fos is an immediate early gene marker of neuronal activation; its reduction indicates decreased stress-driven neural activity in anxiety- and fear-processing circuits
- The amygdala suppression is particularly significant as this structure is central to fear conditioning and anxiety responses
- Hypothalamic c-Fos reduction suggests DSIP modulates the HPA axis stress response at its central origin
- DSIP and its clinical formulation Deltaran showed anxiolytic and stress-protective effects without sedation at effective doses
- The findings support DSIP's role as a stress-response normalizer rather than a CNS depressant
Study Design
Animal in vivo study using rodent acute stress paradigms. DSIP was administered prior to stress exposure. Brain tissue was collected and processed for c-Fos immunohistochemistry to map stress-activated neuronal populations across limbic structures (amygdala, hippocampus, hypothalamus, prefrontal cortex). Quantitative comparison of c-Fos-positive neurons between DSIP-treated and vehicle-treated stressed animals.
Limitations
- Animal model; direct translation of limbic c-Fos data to human anxiety/stress disorders is uncertain
- Acute stress paradigms may not reflect chronic stress conditions relevant to clinical presentations
- c-Fos is an indirect marker of neuronal activity with temporal limitations
- Specific receptor mechanisms mediating DSIP's limbic effects were not identified
- Deltaran formulation details and bioequivalence to pure DSIP not fully characterized
Clinical Relevance
This study provides a neuroanatomical basis for DSIP's stress-protective and anxiolytic properties. The suppression of stress-induced activation in the amygdala, hippocampus, and hypothalamus maps onto the neural circuits implicated in anxiety disorders, PTSD, and stress-related insomnia. For clinicians, this supports using DSIP not only for sleep but also for stress-related conditions where limbic hyperactivation contributes to symptomatology. The lack of sedation at anxiolytic doses is clinically advantageous compared to benzodiazepines.
Related
#research #animal-in-vivo #evidence-level-V